Emergence of Dalbavancin Non-Susceptible, Vancomycin-Intermediate Staphylococcus Aureus (VISA) After Treatment of MRSA Central Line-Associated Bloodstream Infection With a Dalbavancin- And Vancomycin-Containing Regimen
Clinical Microbiology and Infection- United Kingdom
doi 10.1016/j.cmi.2017.07.028
Full Text
Abstract
Available in
Date
April 1, 2018
Authors
Publisher
Elsevier BV